Literature DB >> 11826134

Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.

Silva Fredduzzi1, Rosario Moratalla, Angela Monopoli, Beatriz Cuellar, Kui Xu, Ennio Ongini, Francesco Impagnatiello, Michael A Schwarzschild, Jiang-Fan Chen.   

Abstract

To investigate the role of A(2A) adenosine receptors in adaptive responses to chronic intermittent dopamine receptor stimulation, we compared the behavioral sensitization elicited by repeated l-DOPA treatment in hemiparkinsonian wild-type (WT) and A(2A) adenosine receptor knock-out (A(2A) KO) mice. Although the unilateral nigrostriatal lesion produced by intrastriatal injection of 6-hydroxydopamine was indistinguishable between WT and A(2A) KO mice, they developed strikingly different patterns of behavioral sensitization after daily treatment with low doses of l-DOPA for 3 weeks. WT mice initially displayed modest contralateral rotational responses and then developed progressively greater responses that reached a maximum within 1 week and persisted for the duration of the treatment. In contrast, any rotational behavioral sensitization in A(2A) KO mice was transient and completely reversed within 2 weeks. Similarly, the time to reach the peak rotation was progressively shortened in WT mice but remained unchanged in A(2A) KO mice. Furthermore, daily l-DOPA treatment produced gradually sensitized grooming in WT mice but failed to induce any sensitized grooming in A(2A) KO mice. Finally, repeated l-DOPA treatment reversed the 6-OHDA-induced reduction of striatal dynorphin mRNA in WT but not A(2A) KO mice, raising the possibility that the A(2A) receptor may contribute to l-DOPA-induced behavioral sensitization by facilitating adaptations within the dynorphin-expressing striatonigral pathway. Together these results demonstrate that the A(2A) receptor plays a critical role in the development and particularly the persistence of behavioral sensitization to repeated l-DOPA treatment. Furthermore, they raise the possibility that the maladaptive dyskinetic responses to chronic l-DOPA treatment in Parkinson's disease may be attenuated by A(2A) receptor inactivation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826134      PMCID: PMC6758487     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

Review 1.  Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia.

Authors:  S Ferré; B B Fredholm; M Morelli; P Popoli; K Fuxe
Journal:  Trends Neurosci       Date:  1997-10       Impact factor: 13.837

2.  Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.

Authors:  T Kanda; M J Jackson; L A Smith; R K Pearce; J Nakamura; H Kase; Y Kuwana; P Jenner
Journal:  Ann Neurol       Date:  1998-04       Impact factor: 10.422

3.  Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.

Authors:  B Y Zeng; B Dass; A Owen; S Rose; C Cannizzaro; B C Tel; P Jenner
Journal:  Neurosci Lett       Date:  1999-12-03       Impact factor: 3.046

4.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

5.  Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.

Authors:  R Bordet; S Ridray; J C Schwartz; P Sokoloff
Journal:  Eur J Neurosci       Date:  2000-06       Impact factor: 3.386

6.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

Review 7.  Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.

Authors:  J M Brotchie
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

8.  Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats.

Authors:  A Monopoli; G Lozza; A Forlani; A Mattavelli; E Ongini
Journal:  Neuroreport       Date:  1998-12-01       Impact factor: 1.837

9.  Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice.

Authors:  J Souilhac; M Poncelet; M Rinaldi-Carmona; G Le Fur; P Soubrié
Journal:  Pharmacol Biochem Behav       Date:  1995-05       Impact factor: 3.533

10.  Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels.

Authors:  M A Cenci; K Campbell; A Björklund
Journal:  Neuroscience       Date:  1993-11       Impact factor: 3.590

View more
  31 in total

1.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

Review 2.  Adenosine A2A receptors and basal ganglia physiology.

Authors:  S N Schiffmann; G Fisone; R Moresco; R A Cunha; S Ferré
Journal:  Prog Neurobiol       Date:  2007-06-26       Impact factor: 11.685

3.  Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia.

Authors:  C-J Hong; H-C Liu; T-Y Liu; D-L Liao; S-J Tsai
Journal:  J Neural Transm (Vienna)       Date:  2005-02-22       Impact factor: 3.575

Review 4.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 5.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 6.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

Review 7.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

Review 8.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

9.  Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice.

Authors:  Douglas S Kim; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

10.  Caffeine consumption and risk of dyskinesia in CALM-PD.

Authors:  Anne-Marie A Wills; Shirley Eberly; Marsha Tennis; Anthony E Lang; Susan Messing; Daniel Togasaki; Caroline M Tanner; Cornelia Kamp; Jiang-Fan Chen; David Oakes; Michael P McDermott; Michael A Schwarzschild
Journal:  Mov Disord       Date:  2013-01-21       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.